TY - JOUR
T1 - Identification of genetic subtypes in follicular lymphoma
AU - Shelton, Victoria
AU - Detroja, Rajesh
AU - Liu, Ting
AU - Isaev, Keren
AU - Silva, Anjali
AU - Passerini, Verena
AU - Bakhtiari, Mehran
AU - Calvente, Lourdes
AU - Hong, Michael
AU - He, Michael Y.
AU - Modi, Saloni
AU - Hershenfeld, Samantha A.
AU - Ludvigsen, Maja
AU - Madsen, Charlotte
AU - Hamilton-Dutoit, Stephen
AU - d’Amore, Francesco Annibale
AU - Brodtkorb, Marianne
AU - Johnson, Nathalie A.
AU - Baetz, Tara
AU - LeBrun, David
AU - Tobin, Josh W.D.
AU - Gandhi, Maher K.
AU - Mungall, Andrew J.
AU - Xu, Wei
AU - Ben-Neriah, Susana
AU - Steidl, Christian
AU - Delabie, Jan
AU - Tremblay-LeMay, Rosemarie
AU - Jegede, Opeyemi
AU - Weigert, Oliver
AU - Kahl, Brad
AU - Evens, Andrew M.
AU - Kridel, Robert
N1 - Publisher Copyright:
© The Author(s) 2024.
PY - 2024/8/7
Y1 - 2024/8/7
N2 - Follicular lymphoma (FL) exhibits considerable variability in biological features and clinical trajectories across patients. To dissect the diversity of FL, we utilized a Bernoulli mixture model to identify genetic subtypes in 713 pre-treatment tumor tissue samples. Our analysis revealed the existence of five subtypes with unique genetic profiles that correlated with clinicopathological characteristics. The clusters were enriched in specific mutations as follows: CS (CREBBP and STAT6), TT (TNFAIP3 and TP53), GM (GNA13 and MEF2B), Q (quiescent, for low mutation burden), and AR (mutations of mTOR pathway-related genes). The subtype Q was enriched for patients with stage I disease and associated with a lower proliferative history than the other subtypes. The AR subtype was unique in its enrichment for IgM-expressing FL cases and was associated with advanced-stage and more than 4 nodal sites. The existence of subtypes was validated in an independent cohort of 418 samples from the GALLIUM trial. Notably, patients assigned to the TT subtype consistently experienced inferior progression-free survival when treated with immunochemotherapy. Our findings offer insight into core pathways distinctly linked with each FL cluster and are expected to be informative in the era of targeted therapies. (Figure presented.)
AB - Follicular lymphoma (FL) exhibits considerable variability in biological features and clinical trajectories across patients. To dissect the diversity of FL, we utilized a Bernoulli mixture model to identify genetic subtypes in 713 pre-treatment tumor tissue samples. Our analysis revealed the existence of five subtypes with unique genetic profiles that correlated with clinicopathological characteristics. The clusters were enriched in specific mutations as follows: CS (CREBBP and STAT6), TT (TNFAIP3 and TP53), GM (GNA13 and MEF2B), Q (quiescent, for low mutation burden), and AR (mutations of mTOR pathway-related genes). The subtype Q was enriched for patients with stage I disease and associated with a lower proliferative history than the other subtypes. The AR subtype was unique in its enrichment for IgM-expressing FL cases and was associated with advanced-stage and more than 4 nodal sites. The existence of subtypes was validated in an independent cohort of 418 samples from the GALLIUM trial. Notably, patients assigned to the TT subtype consistently experienced inferior progression-free survival when treated with immunochemotherapy. Our findings offer insight into core pathways distinctly linked with each FL cluster and are expected to be informative in the era of targeted therapies. (Figure presented.)
UR - http://www.scopus.com/inward/record.url?scp=85200668142&partnerID=8YFLogxK
U2 - 10.1038/s41408-024-01111-w
DO - 10.1038/s41408-024-01111-w
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
C2 - 39112453
AN - SCOPUS:85200668142
SN - 2044-5385
VL - 14
JO - Blood Cancer Journal
JF - Blood Cancer Journal
IS - 1
M1 - 128
ER -